This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Neuro-ophthalmology  • Neurology, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Daniel C. Payne, PhD, MSPH; Charles E. Rose Jr, PhD; John Kerrison, MD; Aaron Aranas, MBA, MPH; Susan Duderstadt, MD, MPH; Michael M. McNeil, MD, MPH

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We thank the author for his letter and are in agreement that this investigation represents just a start toward understanding whether or not anthrax vaccination is related to specific health end points. We are currently conducting other studies on this topic, which may add to this body of knowledge.¹

Our decision to analyze an 18-week period following vaccination followed the guidance of epidemiologists, clinicians, and a neuro-ophthalmologist who participated in this optic neuritis study. We describe this decision as a major strength of the study² as it decreases the likelihood that an alternate causation was introduced during the study period. Many neurological disorders do have substantial latency periods; however, a long latency period does not appear to be characteristic of potentially vaccine-mediated . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Adverse Reactions to Anthrax Vaccine (eg, Optic Neuritis) May Be More Complex or Delayed Than Reported Initially by Payne et al (2006)
Walter Richard Schumm
Arch Neurol. 2007;64(3):457-458.
EXTRACT | FULL TEXT